Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Lenalidomide in HMA-Refractory MDS
NCT01246076Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2011
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in myelodysplastic syndrome (MDS), sponsored by Washington University School of Medicine. Started Jun 2011; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01246076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01246076.